Laporkan Masalah

Perbedaan Nilai Rasio Vascular Endothelial Growth Factor/Endostatin Serum Pada Pasien Kanker Payudara Metastasis dan Non-Metastasis

Swastika Dewi , dr. Andaru D., M.Kes, Sp.PK(K) & dr. Osman S., DMM, MSc, Sp.PK(K)

2012 | Skripsi | S1 PENDIDIKAN DOKTER

Latar Belakang: Peningkatan kadar Vascular endothelial growth factor dan endostatin sering terdeteksi pada berbagai jenis tumor ganas termasuk kanker payudara dan sering dihubungkan dengan prognosis. Salah satu faktor prognosis kanker payudara adalah status metastasis kelenjar dan metastasis jauh. Timbul pertanyaan apakah rasio VEGF/endostatin berbeda antara kanker payudara metastasis dan nonmetastasis. Tujuan: Penelitian ini bertujuan mengetahui perbedaan nilai rasio VEGF/endostatin pada kanker payudara metastasis dan nonmetastasis. Metode: Empat puluh pasien penderita kanker payudara diambil sampel darah kemudian dilakukan pemeriksaan kadar VEGF dan endostatin dengan alat imunology analyzer Rayto. Subyek dikelompokkan berdasarkan kejadian metastasis menjadi nonmetastasis (NO, MO) dan metastasis (selain NO, MO) kemudian dianalisis perbedaan rasio VEGF/endostatin pada kedua kelompok. Hasil: Median rasio VEGF/endostatin pada kelompok nonmetastasis kelenjar (NO) dan metastasis kelenjar (N1) atau lebih adalah 0,004 dan 0,003, dengan hasil uji statistik menunjukkan p=0,715. Median pada kelompok nonmetastasis jauh (MO) adalah 0,004 dan kelompok metastasis jauh (M1) adalah 0,003 dengan p=0,357. Pada kelompok nonmetastasis (NO, MO) median rasio VEGF/endostatin adalah 0,004 dan kelompok metastasis (selain NOMO) adalah 0,003 dengan p-0,715. Kesimpulan: Nilai rasio VEGF/endostatin tidak berbeda antara kelompok pasien kanker payudara metastasis dan nonmetastasis. Diperlukan penelitian lebih lanjut untuk mengevaluasi perannya dalam menggambarkan progresivitas kanker dengan pengendalian faktor perancu secara ketat.

Background: Increased level of Vascular endothelial growth factor and endostatin are frequently detected in various types of malignancy, including breast cancer, and are often associated with prognosis. One of the prognostic factors of breast cancer is lymph node and distant metastases. These facts lead to question whether there are any difference of VEGF/endostatin ratio in metastases and nonmetastases breast cancer. Objective: The aim of this study is to know the difference of VEGF/endostatin ratio between metastases and nonmetastases breast cancer in patients who have not received any treatment. Methods: Forty newly diagnosed breast cancer patients were examined their VEGF and endostatin level using Enzyme-Linked Immunosorbent Assay (ELISA) technique from the serum sample. Metastasis information was collected from the patient medical status. Subjects were categorized based on metastases status to nonmetastases group (NO, MO) and metastases group (else), then the difference in VEGF/endostatin between two groups was analyzed. Results: The median of VEGF/endostatin ratio in non- regional lymph node metastases (NO) and with regional lymh node metastases (N1 or more) groups were 0,004 and 0,003, with statistical result p=0,715. Median in non- distant metastases (MO) group was 0,004 and distant metastases (M1) group was 0,003 with p=0,357. In nonmetastases (NOMO) group, the median was 0,004 and in metastases group was 0,003 with p=0,715. Conclusion: There is no difference of VEGF/endostatin ratio in nonmetastases and metastases breast cancer patients. Furher research with strictly controlled confounding factors is needed to evaluate its role in describing cancer progressivity.

Kata Kunci : kanker endothelial growth VEGF/endostatin.

  1. S1-FKU-2012-265221-abstract.pdf  
  2. S1-FKU-2012-265221-bibliography.pdf  
  3. S1-FKU-2012-265221-tableofcontent.pdf  
  4. S1-FKU-2012-265221-title.pdf